Katriona Harrison

Katriona Harrison

Auto-generated profile, based on publicly available information

Katriona Harrison

School of Chemistry and Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Sydney, Sydney, NSW 2006, Australia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2023 in Nature Reviews Chemistry
Verified
Journal Article
Closed access
PDF file
KHKatriona Harrison
Katriona Harrison
AMAngus S. Mackay
Angus S. Mackay
LKLucas Kambanis
Lucas Kambanis
JMJoshua W. C. Maxwell
Joshua W. C. Maxwell
RPRichard J. Payne
Richard J. Payne

4 December 2024 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
BZBelinda B. Zhang
Belinda B. Zhang
KHKatriona Harrison
Katriona Harrison
YZYichen Zhong
Yichen Zhong
JMJoshua W. C. Maxwell
Joshua W. C. Maxwell
DFDaniel J. Ford
Daniel J. Ford
RPRichard J. Payne
Richard J. Payne

4 February 2026 in Biochemical Journal
Verified
Journal Article
Open access
JBJessica A. Buchanan
Jessica A. Buchanan
OLOlivia Lavidis
Olivia Lavidis
NSNicholas Shields
Nicholas Shields
KHKatriona Harrison
Katriona Harrison
HNHuy T. Nguyen
Huy T. Nguyen
MSMargaret Sunde
Margaret Sunde
Receptor interacting protein kinase 3 (RIPK3) is a central regulator of necroptosis and a key mediator of inflammatory signalling. Its function is orchestrated through RIP homotypic interaction motif (RHIM)-dependent interactions with other RHIM-containing adapter proteins, forming amyloid-structured necrosomes that trigger kinase activation and subsequently lead to immunogenic cell lysis. Necroptosis eliminates infected or damaged cells and provokes a strong inflammatory response. Dysregulated necroptosis is implicated in chronic inflammatory diseases and associated with ischaemic injury. Despite separate structural elucidation of the isolated RIPK3 kinase domain and the amyloid fibrils formed by the RIPK3 RHIM-containing region, visualising full-length human RIPK3 in live cells remains challenging due to a lack of specific tools. To address this, we employed random non-standard peptide integrated discovery (RaPID) mRNA display to identify cyclic peptides that bind the RHIM-containing region of RIPK3 during its assembly into amyloid fibrils. Three peptides were selected for characterisation and demonstrate utility in visualising RIPK3 in human cells. These peptides represent promising tools for probing RIPK3 localisation and modulating its function.

6 November 2026 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AMAngus S. Mackay
Angus S. Mackay
JMJoshua W. C. Maxwell
Joshua W. C. Maxwell
KHKatriona Harrison
Katriona Harrison
HAHarry P. Aitken
Harry P. Aitken
JMJosé A. Manso
José A. Manso
RPRichard J. Payne
Richard J. Payne

6 November 2025 in bioRxiv
Verified
Preprint
Open access
JBJessica A. Buchanan
Jessica A. Buchanan
OLOlivia Lavidis
Olivia Lavidis
NSNicholas Shields
Nicholas Shields
KHKatriona Harrison
Katriona Harrison
HNHuy T. Nguyen
Huy T. Nguyen
MSMargaret Sunde
Margaret Sunde
Receptor Interacting Protein Kinase 3 (RIPK3) is a central regulator of necroptosis and a key mediator of inflammatory signaling. Its function is orchestrated through RIP Homotypic Interaction Motif (RHIM)-dependent interactions with other RHIM-containing adapter proteins, forming amyloid-structured necrosomes that trigger kinase activation and subsequently lead to immunogenic cell lysis. Necroptosis eliminates infected or damaged cells and provokes a strong inflammatory response. Dysregulated necroptosis is implicated in chronic inflammatory diseases and associated with ischaemic injury. Despite separate structural elucidation of the isolated RIPK3 kinase domain and the amyloid fibrils formed by the RIPK3 RHIM-containing region, visualizing full-length human RIPK3 in live cells remains challenging due to a lack of specific tools. To address this, we employed Random Non-standard Peptide Integrated Discovery (RaPID) mRNA display to identify cyclic peptides that bind the RHIM-containing region of RIPK3 during its assembly into amyloid fibrils. Three peptides were selected for characterisation and demonstrate utility in visualizing RIPK3 in human cells. These peptides represent promising tools for probing RIPK3 localisation and modulating its function.